Antibody Therapeutics Lab
Our research focuses on two key areas: the mechanisms that govern the structure, function and evolution of the human antibody repertoire; and the molecular engineering of antibodies and cytokines for basic and translational research applications.
![Daniel Christ](https://images.contentstack.io/v3/assets/blt324fd0a04af716e6/blt67feb5ecbdb79f52/64a6977388a8dc93d1e43fab/100363-daniel_christ.jpg?crop=1:1,smart&fit=bounds&width=55&height=55)
Lab Leader
Our studies have identified mechanisms that control the stability of human antibody therapeutics – blockbuster agents – which are among the fastest growing class of drugs in the pharmaceutical sector. Our lab is part of Garvan’s Precision Immunology Program and has extensive collaborative programs, which have highlighted the role of cytokines and membrane receptors in the development of protective immunity. We are applying our genetic engineering technology to structural targets, and to therapeutic targets in cancer and inflammatory diseases, to develop next-generation reagents for imaging and therapeutic applications.
Research team
Professor Daniel Christ
View ProfileDr David Langley
View ProfileJake Henry
View ProfileJenny Jackson
View ProfileHelen Lenthall
View ProfileSacha Zinn
View ProfileCristian David Pena Martinez
View Profile